Tonix Pharmaceuticals Hol... (TNXP)
NASDAQ: TNXP
· Real-Time Price · USD
36.85
4.87 (15.23%)
At close: Jun 16, 2025, 3:59 PM
36.95
0.27%
After-hours: Jun 16, 2025, 07:47 PM EDT
15.23% (1D)
| Bid | 36.02 |
| Market Cap | 271.11M |
| Revenue (ttm) | 10.04M |
| Net Income (ttm) | -115.1M |
| EPS (ttm) | 356.28 |
| PE Ratio (ttm) | 0.1 |
| Forward PE | -5.7 |
| Analyst | Strong Buy |
| Ask | 37 |
| Volume | 709,178 |
| Avg. Volume (20D) | 1,221,976 |
| Open | 32.00 |
| Previous Close | 31.98 |
| Day's Range | 31.35 - 36.89 |
| 52-Week Range | 6.76 - 137.00 |
| Beta | 2.10 |
About TNXP
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol TNXP
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for TNXP stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts4 days ago
-8.41%
Tonix Pharmaceuticals shares are trading lower aft...
Unlock content with
Pro Subscription
2 months ago
+32.48%
Tonix Pharmaceutical shares are trading higher after the company announced the FDA will not require an advisory committee for Tnx-102 SL.
14 hours ago · seekingalpha.com
Tonix Pharmaceuticals: Big Risk, Bigger Reward - Initiating With A BuyI'm initiating Tonix Pharmaceuticals Holding Corp. with a Buy rating, eyeing a rally on potential FDA approval for flagship drug Tonmya in August. Tonmya targets fibromyalgia, a large, underserved mar...
2 months ago · seekingalpha.com
Tonix Pharmaceuticals: Potential To Have 'First' New Fibromyalgia Drug In 15 YearsPDUFA date of August 15th of 2025 set to review on whether or not TNX-102 SL should be approved to treat patients with Fibromyalgia. The company announced that the FDA will not require an Advisory Com...
